Proprietary Business Overview

Duramed Pharmaceuticals, Inc. is Barr's North American proprietary products subsidiary and an innovator in women's healthcare pharmaceutical products, focusing product development and marketing activities primarily on products for women. Since it was acquired by Barr in 2001, Duramed has steadily grown to a $400+ million annual business with over 400 employees, 27 marketed products, aggressive business-development activities, and more than a dozen R&D projects in various stages of development.

Duramed focuses on providing patients with an array of women's healthcare products, with particular emphasis on developing and marketing products that serve reproductive needs, including oral, intrauterine and emergency contraceptives, and menopausal needs, including estrogen therapy.

Proprietary pharmaceutical products are sold under the Duramed label in the U.S., with some products also marketed in Canada through distribution agreements with third parties. Although these products involve substantially higher risk to bring to market and more extensive research and development activities than generic pharmaceuticals, proprietary products offer the potential for a longer period of market or product exclusivity and greater returns than most generic products. However, proprietary products require greater sales and marketing expenses because of the need to promote them directly to physicians and consumers.

Duramed Pharmaceuticals, Inc. is the proud title sponsor of the DURAMED FUTURES® Tour, the official developmental tour of the Ladies Professional Golf Association (LPGA). For more information, visit www.duramedfuturestour.com.